ANEB
Anebulo Pharmaceuticals, Inc.
Key Financials
Operating Income
$-9223481
↓ 11.0%
EPS (Diluted)
$-0.25
↑ 21.9%
Total Assets
$12.1M
↑ 198.2%
Net Income
$-8484763
↓ 3.5%
Shareholders' Equity
$11.7M
↑ 205.8%
Cash & Equivalents
$11.6M
↑ 275.8%
Total Liabilities
$487688.00
↑ 87.2%
Operating Cash Flow
$-6349687.00
↑ 21.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 15-12G | 3/2/2026 | View on SEC |
| 25 | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/13/2026 | View on SEC |
| 10-Q | 2/12/2026 | View on SEC |
| 8-K | 2/12/2026 | View on SEC |
| 8-K | 2/6/2026 | View on SEC |
| SC 13E3/A | 1/29/2026 | View on SEC |
| 8-K | 1/29/2026 | View on SEC |
| SC 13E3/A | 1/27/2026 | View on SEC |
| 8-K | 1/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ANEB |
| Company Name | Anebulo Pharmaceuticals, Inc. |
| CIK | 1815974 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0630 |
| State of Incorporation | DE |
| Phone | 737 203 5270 |